In the evolving landscape of oncology, Radioligand Therapy (RLT) is emerging as a transformative approach that combines the power of diagnostics and therapeutics into a single, highly targeted modality. At Infosys, we recognize the potential of RLT to revolutionize cancer care and are committed to enabling this shift through digital innovation and strategic partnerships.
Why Pharma Companies Are Investing in RLT Imaging Systems
- Strategic Control: Integrating diagnostics and therapy enhances clinical outcomes and commercial scalability.
- Data Ownership: Proprietary imaging data enables deeper insights into patient response and treatment optimization.
- Innovation Enablement: RLT systems support companion diagnostics, clinical trials, and pipeline expansion.
How is RLT’s mode of action?
RLTs consist of two key components:
- A radioactive particle (which can be customized for different therapeutic needs)
- A ligand that binds to specific markers on cancer cells
The ligand guides the radioisotope to target cancer cells, even those that have metastasized. This mechanism allows for precise destruction of tumor cells and components of the tumor microenvironment (TME), while sparing healthy tissue—ultimately aiming to improve quality of life for patients.
Why is RLT a Game Changer?
Radioligand Imaging (RLT) is transforming cancer care by shifting the focus from generalized treatment to precision-guided, molecular-level intervention. Unlike traditional imaging that only shows anatomical structures.
1. Theranostic Capability
Combines diagnosis and therapy in one step—targeting and treating cancer simultaneously.
2. Highly Targeted Mechanism
Radioligands bind specifically to cancer cells, delivering radiation directly to tumors while sparing healthy tissue.
3. Functional Imaging Insights
Goes beyond anatomy to reveal blood flow, metabolism, and receptor activity for early detection and monitoring.
4. Enhanced Safety and Efficacy
Fewer side effects and better outcomes, especially for metastatic or resistant cancers.
5. Personalized Treatment Planning
Enables tailored therapy by assessing tumor burden and response in real time.
How Infosys Supports RLT Transformation
At Infosys, we empower pharma and healthcare organizations to scale RLT adoption through:
- Digital Infrastructure: Building platforms for data integration, AI-driven imaging analytics, and clinical decision support.
- Partner Ecosystem Enablement: Orchestrating vendor ecosystems to accelerate RLT deployment and operational excellence.
- Regulatory & Compliance Support: Ensuring imaging systems meet global standards for safety, efficacy, and data governance.
- Change Management: Driving clinical adoption, training, and workflow integration across oncology networks.
Conclusion
Radioligand Imaging is not just a technological advancement—it’s a paradigm shift in oncology care. As pharma companies embrace this precision-driven approach, Infosys stands ready to support the transformation with cutting-edge digital solutions, strategic consulting, and deep domain expertise.
